从2013年到2022年,改变前线AML治疗模式
Joseph M Brandwein1, Kurt Ebeling1, Lei Ding2
1Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Leukemia research
|July 19, 2023
概括
老年急性髓性白血病 (AML) 患者越来越多地接受非密集治疗 (NIT),改善反应率和生存率. 然而,NIT的整体存活率仍然低于最佳水平,这表明需要在AML治疗方面取得进一步进展.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 现实世界的证据研究研究.
背景情况:
- 急性髓性白血病 (AML) 治疗已经发展,需要对当代治疗模式进行分析.
- 了解老年AML患者治疗的转变对于优化护理至关重要.
研究的目的:
- 为了比较2013-2016年和2021-2022年之间新诊断的AML患者的治疗模式.
- 评估老年AML患者的非密集治疗 (NIT) 使用和结果的变化.
主要方法:
- 对AML患者的真实世界治疗数据的回顾性分析.
- 两个不同的时间段之间的治疗方式 (密集型,非密集型,没有) 和结果 (完整反应,整体存活) 的比较.
主要成果:
- 在70岁以上的患者中观察到NIT使用的显著增加 (2021-22年65% vs. 2013-16年44%).
- 对于NIT患者来说,完全应答率 (69%与24%) 和整体存活率 (11.5与7.8个月) 显著改善.
- 70岁以下患者的治疗模式保持不变;较年长的农村患者更有可能拒绝治疗.
结论:
- 老年AML患者的NIT增加与改善的结果相关,可能是由于更有效的治疗选择.
- 尽管取得了进展,但对AML的非密集治疗的整体存活率仍然低于最佳水平,这凸显了继续研究和开发的必要性.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.4K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K